eMC - trusted, up to date and comprehensive information about medicines

This page has been designed specifically for printing. The full document can be found on the eMC - where you will find trusted, up to date and comprehensive information about medicines.

The eMC provides the latest approved prescribing information (SPCs) and patient information leaflets (PILs) for UK licensed medicines.


Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone: +44 (0)1494 567 567
Fax: +44 (0)1494 567 568
WWW: http://www.janssen-cilag.co.uk
WWW: http://www.janssen-medinfo.co.uk
Medical Information Direct Line: +44 (0)800 731 8450
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +44 (0)800 731 5550
Medical Information Fax: +44 (0) 1494 567 445

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 28/02/2014

Haldol 5mg Tablets



1. Name of the medicinal product

HALDOL Tablets 5 mg


2. Qualitative and quantitative composition

Haloperidol 5 mg.


3. Pharmaceutical form

Tablets.


4. Clinical particulars

4.1 Therapeutic indications

Adults:

• Schizophrenia: treatment of symptoms and prevention of relapse

• Other psychoses: especially paranoid

• Mania and hypomania

• Mental or behavioural problems such as aggression, hyperactivity and self mutilation in the mentally retarded and in patients with organic brain damage

• As an adjunct to short term management of moderate to severe psychomotor agitation, excitement, violent or dangerously impulsive behaviour

• Intractable hiccup

• Restlessness and agitation in the elderly

• Gilles de la Tourette syndrome and severe tics.

Children:

• Childhood behavioural disorders, especially when associated with hyperactivity and aggression

• Gilles de la Tourette syndrome

• Childhood schizophrenia


4.2 Posology and method of administration

For oral administration.

Dosage for all indications should be individually determined and is best initiated and titrated under close clinical supervision. To determine initial dose, consideration should be given to the patient's age, severity of symptoms and previous response to neuroleptic drugs.

Patients who are elderly or debilitated or those with previously reported adverse reactions to neuroleptic drugs may require less Haldol. The normal starting dose should be halved, followed by a gradual titration to achieve optimal response.

Haldol should be used at the minimum dose that is clinically effective.

Adults:

Schizophrenia, psychoses and mania

Use as an antipsychotic agent for schizophrenia, psychoses, mania and hypomania, organic brain damage (depending on symptoms).

Acute phase:

Doses between 2 and 20 mg/day should be administered either as a single dose or in divided doses.

Chronic phase:

1-3 mg orally three times a day, may be increased up to 20 mg per day in divided doses, depending on the response.

Psychomotor anti-agitation

Use as a psychomotor anti-agitation agent for mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms), violent or dangerously impulsive behaviour, Gilles de la Tourette syndrome, severe tics, intractable hiccup.

Adults:

Acute phase:

Moderate symptomatology: 1.5-3 mg twice or three times daily

Severe symptomatology/resistant patients: 3-5 mg twice or three times daily

Chronic phase:

0.5-1 mg three times a day orally, may be increased to 2-3 mg three times a day, if required, to obtain a response.

Once satisfactory control of symptoms has been achieved dosage should be gradually reduced to the lowest effective maintenance dose. Too rapid a dosage reduction should be avoided.

Restlessness or agitation in the elderly

Treatment should start with half the dosage stated for adults and adjusted according to the results if necessary.

Children:

Childhood Schizophrenia

The recommended doses below provide a total dose in the approximate range 0.03 to 0.15 mg/kg/day, when administered orally in divided doses (two or three times a day).

Children 3 to 12 years of age

The recommended

- starting dose is a total 0.5 mg/day orally, preferably in divided doses

- target dose range is a total 1 to 4 mg/day orally, in divided doses

- maximum dose is a total 6 mg/day orally, in divided doses.

Adolescents 13 to 17 years of age

The recommended

- starting dose is a total 0.5 mg/day orally, preferably in divided doses

- target dose range is a total 1 to 6 mg/day orally, in divided doses

- maximum dose is a total 10 mg/day orally, in divided doses.

Childhood Psychomotor anti-agitation

The recommended doses below provide a total dose in the approximate range 0.02 to 0.075 mg/kg/day when administered orally in divided doses (two to three times a day).

Children 3 to 12 years of age

The recommended

- starting dose is a total 0.25 mg/day orally, preferably in divided doses.

- target dose range is a total 0.5 to 3 mg/day orally, in divided doses.

- maximum dose is a total 3 mg/day orally, in divided doses.

Adolescents 13 to 17 years of age

The recommended

- starting dose is a total 0.25 mg/day orally, preferably in divided doses.

- target dose range is a total 2 to 6 mg/day orally, in divided doses.

- maximum dose is a total 6 mg/day orally, in divided doses.


4.3 Contraindications

Comatose states, CNS depression, Parkinson's disease, known hypersensitivity to haloperidol, lesions of basal ganglia.

In common with other neuroleptics, haloperidol has the potential to cause rare prolongation of the QT interval. Use of haloperidol is therefore contra-indicated in patients with clinically significant cardiac disorders e.g. recent acute myocardial infarction, uncompensated heart failure, arrhythmias treated with class IA and III antiarrhythmic medicinal products, QTc interval prolongation, history of ventricular arrhythmia or torsades de pointes clinically significant bradycardia, second or third degree heart block and uncorrected hypokalaemia. Haloperidol should not be used concomitantly with other QT prolonging drugs (see section 4.5, Interactions)


4.4 Special warnings and precautions for use

Cases of sudden death have been reported in psychiatric patients receiving antipsychotic drugs, including haloperidol.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

Haldol is not licensed for the treatment of dementia-related behavioural disturbances.

Cardiovascular effects

Very rare reports of QT prolongation and/or ventricular arrhythmias, in addition to rare reports of sudden death, have been reported with haloperidol. They may occur more frequently with high doses and in predisposed patients.

The risk-benefit of haloperidol treatment should be fully assessed before treatment is commenced and patients with risk factors for ventricular arrhythmias such as cardiac disease, family history of sudden death and/or QT prolongation; uncorrected electrolyte disturbances, subarachnoid haemorrhage, starvation or alcohol abuse, should be monitored carefully (ECGs and potassium levels), particularly during the initial phase of treatment, to obtain steady plasma levels. The risk of QT prolongation and/or ventricular arrhythmias may be increased with higher doses (see Sections 4.8 and 4.9) or with parenteral use, particularly intravenous administration. ECG monitoring should be performed for QT interval prolongation and for serious cardiac dysrhythmias if Haldol is administered intravenously.

Haloperidol should be used with caution in patients known to be slow metabolisers of CYP2D6, and during use of cytochrome P450 inhibitors. Concomitant use of antipsychotics should be avoided. (See Section 4.5)

Baseline ECG is recommended prior to treatment in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination. During therapy, the need for ECG monitoring (e.g. at dose escalation) should be assessed on an individual basis. Whilst on therapy, the dose should be reduced if QT is prolonged, and haloperidol should be discontinued if the QTc exceeds 500 ms.

Periodic electrolyte monitoring is recommended, especially for patients taking diuretics, or during intercurrent illness.

An approximately 3-fold increase risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Haloperidol should be used with caution in patients with risk factors for stroke.

Neuroleptic malignant syndrome

In common with other antipsychotic drugs, Haldol has been associated with neuroleptic malignant syndrome: a rare idiosyncratic response characterised by hyperthermia, generalised muscle rigidity, autonomic instability, altered consciousness. Hyperthermia is often an early sign of this syndrome. Antipsychotic treatment should be withdrawn immediately and appropriate supportive therapy and careful monitoring instituted.

Tardive dyskinesia

As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or after drug discontinuation. The syndrome is mainly characterised by rhythmic involuntary movements of the tongue, face, mouth or jaw. The manifestations may be permanent in some patients. The syndrome may be masked when treatment is reinstituted, when the dosage is increased or when a switch is made to a different antipsychotic drug. Treatment should be discontinued as soon as possible.

Extrapyramidal symptoms

In common with all neuroleptics, extrapyramidal symptoms may occur, e.g. tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia.

Antiparkinson drugs of the anticholinergic type may be prescribed as required, but should not be prescribed routinely as a preventive measure. If concomitant antiparkinson medication is required, it may have to be continued after stopping Haldol if its excretion is faster than that of Haldol in order to avoid the development or aggravation of extrapyramidal symptoms. The physician should keep in mind the possible increase in intraocular pressure when anticholinergic drugs, including antiparkinson agents, are administered concomitantly with Haldol.

Seizures/Convulsions

It has been reported that seizures can be triggered by Haldol. Caution is advised in patients suffering from epilepsy and in conditions predisposing to convulsions (e.g., alcohol withdrawal and brain damage).

Hepatobiliary concerns

As Haldol is metabolised by the liver, caution is advised in patients with liver disease. Isolated cases of liver function abnormalities or hepatitis, most often cholestatic, have been reported.

Endocrine system concerns

Thyroxin may facilitate Haldol toxicity. Antipsychotic therapy in patients with hyperthyroidism should be used only with great caution and must always be accompanied by therapy to achieve a euthyroid state.

Hormonal effects of antipsychotic neuroleptic drugs include hyperprolactinaemia, which may cause galactorrhoea, gynaecomastia and oligo- or amenorrhoea. Very rare cases of hypoglycaemia and of Syndrome of Inappropriate ADH Secretion have been reported.

Venous thromboembolism

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Haldol and preventive measures undertaken.

Additional considerations

In schizophrenia, the response to antipsychotic drug treatment may be delayed. Also, if drugs are withdrawn, recurrence of symptoms may not become apparent for several weeks or months.

Acute withdrawal symptoms including nausea, vomiting and insomnia have very rarely been described after abrupt cessation of high doses of anti-psychotic drugs. Relapse may also occur and gradual withdrawal is advisable.

As with all antipsychotic agents, Haldol should not be used alone where depression is predominant. It may be combined with antidepressants to treat those conditions in which depression and psychosis coexist.

Caution is advised in patients with renal failure and phaeochromocytoma.

Available safety data in the paediatric population indicate a risk of extrapyramidal symptoms, including tardive dyskinesia, and sedation. No long-term safety data are available.


4.5 Interaction with other medicinal products and other forms of interaction

Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended (see section 4.3-Contraindications).

Examples include certain antiarrhythmics, such as those of Class 1A (such as quinidine, disopyramide and procainamide) and class III (such as amiodarone, sotalol and dofetilide), certain antimicrobials (sparfloxacin, moxifloxacin, erythromycin IV), tricyclic antidepressants (such as amitriptyline), certain tetracyclic antidepressants (such as maprotiline), other neuroleptics (e.g. phenothiazines, pimozide and sertindole), certain antihistamines (such as terfenadine), cisapride, bretylium and certain antimalarials such as quinine and mefloquine. This list is not comprehensive.

Concurrent use of drugs causing electrolyte imbalance may increase the risk of ventricular arrhythmias and is not recommended (see section 4.4-Special Warnings and Precautions for Use). Diuretics, in particular those causing hypokalaemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Haloperidol is metabolised by several routes, including glucuronidation and the cytochrome P450 enzyme system (particularly CYP 3A4 or CYP 2D6). Inhibition of these routes of metabolism by another drug or a decrease in CYP 2D6 enzyme activity may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation. In pharmacokinetic studies, mild to moderately increased haloperidol concentrations have been reported when haloperidol was given concomitantly with drugs characterised as substrates or inhibitors of CYP 3A4 or CYP 2D6 isozymes, such as, itraconazole, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, and promethazine. A decrease in CYP2D6 enzyme activity may result in increased haloperidol concentrations. Increases in QTc and extrapyramidal symptoms have been observed when haloperidol was given with a combination of the metabolic inhibitors ketoconazole (400 mg/day) and paroxetine (20 mg/day). It may be necessary to reduce the haloperidol dosage.

Effect of Other Drugs on Haloperidol

When prolonged treatment with enzyme-inducing drugs such as carbamazepine, phenobarbital, rifampicin is added to Haldol therapy, this results in a significant reduction of haloperidol plasma levels. Therefore, during combination treatment, the Haldol dose should be adjusted, when necessary. After stopping such drugs, it may be necessary to reduce the dosage of Haldol.

Sodium valproate, a drug known to inhibit glucuronidation, does not affect haloperidol plasma concentrations.

Effect of Haloperidol on Other Drugs

In common with all neuroleptics, Haldol can increase the central nervous system depression produced by other CNS-depressant drugs, including alcohol, hypnotics, sedatives or strong analgesics. An enhanced CNS effect, when combined with methyldopa, has also been reported.

Haldol may antagonise the action of adrenaline and other sympathomimetic agents and reverse the blood-pressure-lowering effects of adrenergic-blocking agents such as guanethidine.

Haldol may impair the antiparkinson effects of levodopa.

Haloperidol is an inhibitor of CYP 2D6. Haldol inhibits the metabolism of tricyclic antidepressants, thereby increasing plasma levels of these drugs.

Other Forms of Interaction

In rare cases, an encephalopathy-like syndrome has been reported in combination with lithium and haloperidol. It remains controversial whether these cases represent a distinct clinical entity or whether they are in fact cases of NMS and/or lithium toxicity. Signs of encephalopathy-like syndrome include confusion, disorientation, headache, disturbances of balance and drowsiness. One report showing symptomless EEG abnormalities on the combination has suggested that EEG monitoring might be advisable. When lithium and haloperidol therapy are used concomitantly, haloperidol should be given in the lowest effective dose and lithium levels should be monitored and kept below 1 mmol/l. If symptoms of encephalopathy-like syndrome occur, therapy should be stopped immediately.

Antagonism of the effect of the anticoagulant phenindione has been reported.

The dosage of anticonvulsants may need to be increased to take account of the lowered seizure threshold.


4.6 Fertility, pregnancy and lactation

The safety of haloperidol in pregnancy has not been established. There is some evidence of harmful effects in some, but not all animal studies. Neonates exposed to antipsychotic drugs (including haloperidol) during the third trimester of pregnancy are at risk of adverse effects including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.

There have been a number of reports of birth defects following foetal exposure to haloperidol for which a causal role for haloperidol cannot be excluded. Haldol should be used during pregnancy only if the anticipated benefit outweighs the risk and the administered dose and duration of treatment should be as low and as short as possible.

Haloperidol is excreted in breast milk. There have been isolated cases of extrapyramidal symptoms in breast-fed children. If the use of Haldol is essential, the benefits of breast feeding should be balanced against its potential risks.


4.7 Effects on ability to drive and use machines

Some degree of sedation or impairment of alertness may occur, particularly with higher doses and at the start of treatment, and may be potentiated by alcohol or other CNS depressants. Patients should be advised not to undertake activities requiring alertness such as driving or operating machinery during treatment, until their susceptibility is known.


4.8 Undesirable effects

The data provided below covers all haloperidol formulations including the Haldol Decanoate formulations.

The safety of Haldol was evaluated in 284 haloperidol-treated subjects who participated in 3 placebo-controlled, and in 1295 haloperidol-treated subjects who participated in sixteen double-blind active comparator-controlled clinical trials. The safety of Haldol decanoate was evaluated in 410 subjects who participated in 3 comparator trials (one comparing haloperidol vs. fluphenazine and two comparing the decanoate formulation to the oral formulation), 9 open label trials and 1 dose responsive trial. Based on pooled safety data from these clinical trials, the most commonly reported (% incidence) Adverse Drug Reactions (ADRs) were: Extrapyramidal disorder (34), Insomnia (19), Agitation (15), Hyperkinesia (13), Headache (12), Psychotic disorder (9), Depression (8), Weight increased (8), Orthostatic hypotension (7) and Somnolence (5).

Including the above mentioned ADRs, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of Haldol and Haldol Decanoate. Frequencies displayed use the following convention:

Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

System Organ Class

Adverse Drug Reactions

Frequency Category

Very Common

(≥ 1/10)

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥ 1/1,000 to < 1/100)

Rare

(≥ 1/10,000 to <1/1,000)

Not Known

Blood and lymphatic System Disorders

  

Leukopenia

 

Agranulocytosis; Neutropenia; Pancytopenia; Thrombo-cytopenia

Immune System Disorders

  

Hypersensitivity

 

Anaphylactic reaction

Endocrine Disorders

   

Hyper-prolactinaemia

Inappropriate antidiuretic hormone secretion

Metabolic and Nutritional Disorders

    

Hypoglycaemia

Psychiatric Disorders

Agitation; Insomnia

Depression; Psychotic disorder

Confusional state; Libido Decreased; Loss of libido; Restlessness

  

Nervous System Disorders

Extrapyramidal disorder; Hyperkinesia; Headache

Tardive dyskinesia; Oculogyric Crisis; Dystonia; Dyskinesia; Akathisia; Bradykinesia; Hypokinesia; Hypertonia; Somnolence; Masked Facies, Tremor; Dizziness

Convulsion; Parkinsonism; Akinesia; Cogwheel rigidity; Sedation; Muscle Contractions Involuntary

Motor dysfunction; Neuroleptic malignant syndrome; Nystagmus;

 

Eye Disorders

 

Visual disturbance;

Vision blurred

  

Cardiac Disorders

  

Tachycardia

 

Ventricular Fibrillation; Torsade de pointes; Ventricular Tachycardia; Extrasystoles

Vascular Disorders

 

Orthostatic Hypotension; Hypotension

   

Respiratory, thoracic and mediastinal Disorders

  

Dyspnoea

Bronchospasm

Laryngeal Oedema; Laryngospasm

Gastrointestinal Disorders

 

Constipation; Dry mouth; Salivary hypersecretion; Nausea; Vomiting

   

Hepatobiliary Disorders

 

Liver function test abnormal

Hepatitis; Jaundice

 

Acute Hepatic Failure; Cholestasis

Skin and subcutaneous tissue disorders

 

Rash

Photosensitivity Reaction; Urticaria; Pruritis; Hyperhidrosis

 

Leukocytoclastic Vasculitis; Dermatitis Exfoliative

Musculoskeletal and Connective Tissue Disorders

  

Torticollis; Muscle rigidity; Muscle Spasms; Musculoskeletal stiffness

Trismus; Muscle Twitching

 

Renal and Urinary Disorders

 

Urinary retention

   

Pregnancy, Puerperium and Perinatal Conditions

    

Drug withdrawal syndrome neonatal (see section 4.6)

Reproductive System and Breast Disorders

 

Erectile dysfunction

Amenorrhoea; Dysmenorrhoea; Galactorrhoea; Breast Discomfort; Breast Pain;

Menorrhagia; Menstrual Disorder; Sexual Dysfunction

Gynaecomastia, Priapism

General Disorders and Administration Site Conditions

  

Gait disturbance; Hyperthermia; Oedema

 

Sudden Death; Face Oedema; Hypothermia

Investigations

 

Weight increased; Weight decreased

 

Electrocardiogram QT prolonged

 

Additional Information

Cardiac effects such as QT-interval prolongation, torsade de pointes, ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia), and cardiac arrest have been reported. These effects may occur more frequently with high doses, and in predisposed patients.

Toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported in patients taking haloperidol. The true incidence of these reports is not known.

Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs- Frequency unknown.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9 Overdose

Symptoms

In general, the manifestations of haloperidol overdosage are an extension of its pharmacological actions, the most prominent of which would be severe extrapyramidal symptoms, hypotension and psychic indifference with a transition to sleep. The risk of ventricular arrhythmias possibly associated with QT-prolongation should be considered. The patient may appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state. Paradoxically hypertension rather than hypotension may occur. Convulsions may also occur.

Treatment

There is no specific antidote to haloperidol. A patent airway should be established and maintained with mechanically assisted ventilation if necessary. In view of isolated reports of arrhythmia ECG monitoring is strongly advised. Hypotension and circulatory collapse should be treated by plasma volume expansion and other appropriate measures. Adrenaline should not be used. The patient should be monitored carefully for 24 hours or longer, body temperature and adequate fluid intake should be maintained.

In cases of severe extrapyramidal symptoms, appropriate anti-Parkinsonian medication should be administered.


5. Pharmacological properties

5.1 Pharmacodynamic properties

Haloperidol acts as a central and peripheral dopamine receptor antagonist. It also has some anticholinergic activity and binds to opiate receptors.


5.2 Pharmacokinetic properties

Pharmacotherapeutic group: Butyrophenone Derivatives: ATC code: NO5A DO1

Haloperidol is rapidly absorbed after oral administration with a bioavailability of 44-74% (mean 60%) after tablets. Variable bioavailability is likely due to inter-individual differences in gastro-intestinal absorption and extent of first-pass hepatic metabolism.

Distribution is rapid to extravascular tissue, haloperidol crosses the blood-brain barrier and is excreted in human breast milk.

Metabolism is by oxidative dealkylation. The elimination half-life is approximately 20 hours, with considerable diurnal variation.


5.3 Preclinical safety data

Only limited data are available, however these show no specific hazards apart from decreased fertility, limited teratogenicity as well as embryo-toxic effects in rodents.

Haloperidol has been shown to block the cardiac hERG channel in several published studies in vitro. In a number of in vivo studies intravenous administration of haloperidol in some animal models has caused significant QTc prolongation, at doses around 0.3 mg/kg i.v., giving Cmax plasma levels 3 to 7 times higher than the effective human plasma concentrations of 4 to 20 ng/ml. These intravenous doses which prolonged QTc did not cause arrhythmias. In some studies higher intravenous doses of 1 to 5 mg/kg haloperidol i.v. caused QTc prolongation and/or ventricular arrhythmias at Cmax plasma levels 19 to 68 times higher than the effective human plasma concentrations.


6. Pharmaceutical particulars

6.1 List of excipients

Lactose monohydrate

Maize starch

Talc

Cottonseed oil - hydrogenated

Indigotindisulphonate sodium (E132)

Purified water*

* not present in final product.


6.2 Incompatibilities

None.


6.3 Shelf life

60 months.


6.4 Special precautions for storage

Do not store above 25°C.

Keep out of reach and sight of children.


6.5 Nature and contents of container

Blister packs of aluminium foil and polyvinylchloride genotherm glass clear.

or

*Bottles of polystyrene (white) and stoppers of low density polyethylene.

or

*Bottles of white polypropylene and stoppers of low density polyethylene.

The strips are packed in cardboard cartons containing 100 tablets per pack.

* Not marketed


6.6 Special precautions for disposal and other handling

None.


7. Marketing authorisation holder

Janssen-Cilag Ltd

50-100 Holmers Farm Way

High Wycombe

Buckinghamshire

HP12 4EG

UK


8. Marketing authorisation number(s)

PL00242/0031R


9. Date of first authorisation/renewal of the authorisation

Date of First Authorisation: 20 June 1986

Date of Renewal of Authorisation: 11 January 2003


10. Date of revision of the text

03 December 2013